---
title: "Varegacestat (AL102) in Desmoid tumors: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Place in treatment, anticipated use, and care setting. Topics: Proposed indication under FDA review, Active surveillance as the first step and active treatment after persistent progression, Treatment choice by anatomical site in the global consensus algorithm, Positioning of gamma secretase inhibitors in the 2023 global consensus update, and 9 further topics. 14 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

- The NDA under FDA review proposes varegacestat “for the treatment of adults with desmoid tumors”.
- The Desmoid Tumor Working Group considers active surveillance the first step after diagnosis in the majority of patients and proposes active treatment only in case of persistent progression. Treatment choice is guided by anatomical site: surgery remains the first option at progression for abdominal wall tumors, systemic therapy is the first option for intra-abdominal, retroperitoneal, and pelvic tumors, and medical therapy is preferred for extremity, girdle, and chest wall tumors and is first line for head and neck and intrathoracic tumors. The group states that no definitive sequence of systemic treatments can be proposed because comparative studies are lacking.
- The 2023 global consensus update addressed the positioning of gamma secretase inhibitors, with nirogacestat the first approved drug for desmoid tumors. NCCN soft tissue sarcoma guidelines version 1.2025, as quoted in a Cigna coverage policy, list Ogsiveo and sorafenib as category 1 and methotrexate-based, imatinib, pazopanib, and doxorubicin-based regimens as category 2A.
- The approved gamma secretase inhibitor, OGSIVEO (nirogacestat), is indicated for adult patients with progressing desmoid tumors who require systemic treatment, at 150 mg orally twice daily until disease progression or unacceptable toxicity. NICE recommends nirogacestat within its marketing authorisation; in its appraisal, current options in England are off-label chemotherapy, off-label tyrosine kinase inhibitors, and surgery, and nirogacestat is expected to displace chemotherapy and best supportive care.
- RINGSIDE Part B enrolled 156 participants with progressive disease (tumor growth of at least 20% within the past 12 months) who were either treatment-naïve with tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.
- Immunome states that systemic therapy is recommended for about 75% of tumors after progression during initial active surveillance, that gamma secretase inhibitors “may ultimately capture much of the market for desmoid tumor therapy”, and that it aims to “Become Standard of Care treatment of Desmoid Tumors”. It describes varegacestat as oral and once daily, estimates “10-11k Actively Managed Patients (US)”, and anticipates that patients may receive about 1.5 to 2 years of treatment, pause, and return for treatment.
- Immunome plans to commercialize in the United States through a targeted sales force designed to reach specialized treatment centers, and its corporate presentation names about 85 sarcoma centers of excellence.

Source: [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/); [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext); [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/); [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf); [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf); [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation); [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion); [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.2.2-2"></a>

### Proposed indication under FDA review

> “today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors.”

Source: [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

<a id="topic-2.2.2.2-3"></a>

### Active surveillance as the first step and active treatment after persistent progression

> “Thus, being cautious and avoiding potential harm in experienced hands, this approach is now considered the first step after diagnosis in majority of the patients.”
> “Neither surgery nor other forms of active treatments are proposed as primary therapy at diagnosis. Considering the biology and unpredictable course of the disease, active treatments should be considered only in case of persistent progression.”
> “A decision towards an active treatment should be postponed until the occurrence of subsequent progression or increase of symptoms burden, assessed with at least two further assessments and possibly not before one year from diagnosis in the absence of fulfilling RECIST progressive disease.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “An initial watchful waiting approach is useful to document actual tumor progression. Active therapies need to be individualized on a multidisciplinary basis for patients with clearly progressing disease.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.2-4"></a>

### Treatment choice by anatomical site in the global consensus algorithm

> “As depicted in the treatment algorithm in Fig. 3, the type of further treatment is generally guided according to the anatomical site and the decision should be made with the patients in a stepwise approach: For abdominal wall DT, surgery is still the first option in case of progression. For intra-abdominal/retroperitoneal/pelvic DT, systemic therapy should be considered as the first treatment option. For extremity/girdles/chest wall DT, again surgery should not be the first treatment option unless the expected morbidity is very low (and only following MDT discussion); medical therapy should be administered preferably.”
> “For head & neck/intrathoracic DT, medical therapy is generally considered the first line option.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.2-5"></a>

### Positioning of gamma secretase inhibitors in the 2023 global consensus update

> “The 2023 update of the global evidence-based consensus guideline focused on the positioning of local therapies alongside surgery and radiotherapy in the treatment algorithm as well as the positioning of the newest class of medical agents, such as γ-secretase inhibitors.”
> “The 2023 consensus guideline is informed by a number of new aspects, including data for local ablative therapies such as cryotherapy; other indications for surgery; and the γ-secretase inhibitor nirogacestat, the first representative of the newest class of medical agents and first approved drug for DT.”

Source: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

<a id="topic-2.2.2.2-6"></a>

### Sequence of systemic therapies

> “In summary, due to the lack of comparative studies we are still not able to propose a definitive sequence of the existing systemic treatment options.”
> “In general, it is reasonable to employ less toxic therapy initially followed by more toxic agents in a stepwise fashion. Out of the variety of possible systemic treatment options, one can be chosen taking into account the (1) level of evidence, (2) overall response rate, (3) PFS rate, (4) ease of administration and (5) expected toxicity of the administered drug following a 5-dimensional model (Fig. 4).”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.2-7"></a>

### NCCN preferred systemic regimens for desmoid tumors

> “The National Comprehensive Cancer Network (NCCN) soft tissue sarcoma guidelines (version 1.2025 – May 2, 2025) recommend the following therapies as”
> “regimens for desmoid tumors (aggressive fibromatosis):”
> “Ogsiveo (category 1), sorafenib (category 1), methotrexate and vinorelbine, methotrexate and vinblastine, imatinib, pazopanib, doxorubicin ± dacarbazine, and Doxil® (liposomal doxorubicin for intravenous injection) [except for Ogsiveo and sorafenib, all other agents listed are category 2A recommendations].”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

<a id="topic-2.2.2.2-8"></a>

### Labeled population and dosing of the approved gamma secretase inhibitor

> “OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.”
> “The recommended dosage of OGSIVEO is 150 mg administered orally twice daily until disease progression or unacceptable toxicity.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

> “Nirogacestat can be used, within its marketing authorisation, as an option to treat progressing desmoid tumours that need systemic treatment in adults.”

Source: [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation)

<a id="topic-2.2.2.2-9"></a>

### Treatment pathway and displaced treatments in England

> “When tumours are asymptomatic and non-threatening, management consists of active surveillance with monitoring and no immediate treatment. If tumours become symptomatic, progress, or threaten function, active treatment may be indicated.”
> “Current treatment options include off-label chemotherapy, off-label tyrosine kinase inhibitors (TKIs) and surgery.”
> “The committee noted that treatment decisions largely depend on the location of the desmoid tumour and its associated symptoms, with treatment options varying across the NHS.”
> “The basket comparator reflected the estimated mix of treatments that nirogacestat is expected to displace in NHS clinical practice, with the proportions of people having chemotherapy and best supportive care adding up to 100%.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.2.2-10"></a>

### RINGSIDE Part B population of treatment-naive and previously treated progressing disease

> “One hundred fifty-six participants with histologically confirmed desmoid tumors with progressive disease (defined as tumor growth of at least 20% within the past 12 months as measured by RECIST v1.1) were enrolled.”
> “Enrolled participants were either treatment-naïve with desmoid tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.2.2-11"></a>

### Company statements of anticipated use

> “Following progression during initial active surveillance, systemic therapy is recommended for ~75% of tumors based on location.”
> “Treatment considerations include tumor progression, symptoms, risk of morbidity, surgical risk, and the need for a fast response. The uptake of OGSIVEO® in the United States in the treatment of desmoid tumors demonstrates the potential for GSIs to address unmet need, and we believe that GSIs may ultimately capture much of the market for desmoid tumor therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “Elevating an Established Class and Solidifying the Role of GSIs in Desmoid Tumor Treatment”
> “Become Standard of Care treatment of Desmoid Tumors”
> “10-11k Actively Managed Patients (US)”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “These findings confirm varegacestat could become standard of care in the treatment of desmoid tumors.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-2.2.2.2-12"></a>

### Oral once-daily administration and anticipated treatment duration

> “Varegacestat is an investigational, oral, once-daily GSI therapy under evaluation for the treatment of desmoid tumors.”
> “Participants who progress while on study are eligible to enter an open-label extension whereby they may receive varegacestat at a dose of 1.2 mg once daily until disease progression or unacceptable toxicity.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “SUPPORT Sustained benefit and adherence with a once-daily treatment”
> “~50% of patients have desmoid tumors for more than 5 years”
> “A Long, Chronic, Treatment Journey”
> “Patients may receive ~1.5–2 years of treatment, pause, and return for treatment”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.2.2-13"></a>

### Care setting in sarcoma centers and specialized treatment centers

> “In the United States, we expect to commercialize the product through a focused internal commercial organization, which would include capabilities in marketing, analytics, market access, and a targeted sales force designed to reach specialized treatment centers.”
> “patient identification and market education efforts focused on the treating community; early market access planning intended to support appropriate patient access; and a build-out of patient support capabilities aligned with the chronic nature of treatment in this population.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “~85 Sarcoma Centers-of-Excellence”
> “SCALE Efficiently expand reach across the community through treatment center growth”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.2.2-14"></a>

### Other products in development for desmoid tumors

> “Parabilis is evaluating the small molecule zolucatetide in a Phase 1/2 study that includes patients with desmoid tumors and plans to initiate a phase 3 registrational trial in 2027.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
